epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
Apitegromab
apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Turqoz

norgestrel/ ethinyl estradiol

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Black Box Warnings .

Smoking and Cardiovascular Events

cigarette smoking incr. risk of serious cardiovascular events from combined hormonal contraceptive use; incr. risk with age (particularly for patients >35 yo) and with number of cigarettes smoked; contraindicated in smokers >35 yo

Adult Dosing .

Dosage forms:  TAB (28-day monophasic pack): 0.3 mg/30 mcg x21 and inert tab x7

Special Note

[additional info]
Info: see Oral Contraceptive Pill (OCP) Hormonal Activity and Therapeutic Equivalence table

contraception

[1 tab PO qd]
Start: day 1 of menstrual cycle or 1st Sunday after onset of menses; Info: D/C >4wk before, restart >2wk after surgery with VTE risk; restart >4wk postpartum or >6wk postpartum if breastfeeding

dysfunctional uterine bleeding, moderate (off-label)

[acute phase]
Dose: 1 tab PO bid x5-7 days, then 1 tab PO qd until all active tabs given in 1 pack, skip inert tabs; Alt: 1 tab PO tid x3 days or until bleeding subsides, then 1 tab PO bid x3-5 days, then 1 tab PO qd until all active tabs given in 1 pack, skip inert tabs
[maintenance phase]
Dose: 1 tab PO qd; Info: may skip inert tabs for extended or continuous cycle; D/C >4wk before, restart >2wk after surgery with VTE risk; restart >4wk postpartum or >6wk postpartum if breastfeeding

dysmenorrhea (off-label)

[1 tab PO qd]
Start: day 1 of menstrual cycle or 1st Sunday after onset of menses; Info: may skip inert tabs for extended or continuous cycle if pain persists; D/C >4wk before, restart >2wk after surgery with VTE risk; restart >4wk postpartum or >6wk postpartum if breastfeeding

emergency contraception (off-label)

[4 tabs PO q12h x2 doses]
Start: ASAP after unprotected intercourse; maximum efficacy within 72h, moderate efficacy within 120h; Info: use white tabs (norgestrel/ethinyl estradiol 0.3 mg/30 mcg); repeat dose if vomiting occurs within 3h

endometriosis (off-label)

[1 tab PO qd]
Start: day 1 of menstrual cycle or 1st Sunday after onset of menses; Info: may skip inert tabs for extended or continuous cycle if pain persists; D/C >4wk before, restart >2wk after surgery with VTE risk; restart >4wk postpartum or >6wk postpartum if breastfeeding

renal dosing

[see below]
renal disease: not defined, caution advised
HD/PD: avoid use

hepatic dosing

[see below]
active hepatic disease: contraindicated

Peds Dosing .

Dosage forms:  TAB (28-day monophasic pack): 0.3 mg/30 mcg x21 and inert tab x7

Special Note

[additional info]
Info: see Oral Contraceptive Pill (OCP) Hormonal Activity and Therapeutic Equivalence table

contraception

[postmenarchal patients]
Dose: 1 tab PO qd; Start: day 1 of menstrual cycle or 1st Sunday after onset of menses; Info: D/C >4wk before, restart >2wk after surgery with VTE risk; restart >4wk postpartum or >6wk postpartum if breastfeeding

dysfunctional uterine bleeding, moderate (off-label)

[acute phase, postmenarchal patients]
Dose: 1 tab PO bid x5-7 days, then 1 tab PO qd until all active tabs given in 1 pack, skip inert tabs; Alt: 1 tab PO tid x3 days or until bleeding subsides, then 1 tab PO bid x3-5 days, then 1 tab PO qd until all active tabs given in 1 pack, skip inert tabs
[maintenance phase, postmenarchal patients]
Dose: 1 tab PO qd; Info: may skip inert tabs for extended or continuous cycle; D/C >4wk before, restart >2wk after surgery with VTE risk; restart >4wk postpartum or >6wk postpartum if breastfeeding

dysmenorrhea (off-label)

[postmenarchal patients]
Dose: 1 tab PO qd; Start: day 1 of menstrual cycle or 1st Sunday after onset of menses; Info: may skip inert tabs for extended or continuous cycle if pain persists; D/C >4wk before, restart >2wk after surgery with VTE risk; restart >4wk postpartum or >6wk postpartum if breastfeeding

emergency contraception (off-label)

[postmenarchal patients]
Dose: 4 tabs PO q12h x2 doses; Start: ASAP after unprotected intercourse; maximum efficacy within 72h, moderate efficacy within 120h; Info: use white tabs (norgestrel/ethinyl estradiol 0.3 mg/30 mcg); repeat dose if vomiting occurs within 3h

endometriosis (off-label)

[postmenarchal patients]
Dose: 1 tab PO qd; Start: day 1 of menstrual cycle or 1st Sunday after onset of menses; Info: may skip inert tabs for extended or continuous cycle if pain persists; D/C >4wk before, restart >2wk after surgery with VTE risk; restart >4wk postpartum or >6wk postpartum if breastfeeding

renal dosing

[see below]
renal disease: not defined, caution advised
HD/PD: avoid use

hepatic dosing

[see below]
active hepatic disease: contraindicated

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@12aee7a7
  • hypersensitivity to drug or ingredient
  • pregnancy
  • <4wk postpartum (non-breastfeeding patients)
  • <6wk postpartum (breastfeeding patients)
  • cancer, estrogen-dependent
  • cancer, progestogen-dependent
  • cancer history, estrogen-dependent
  • cancer history, progestogen-dependent
  • breast CA
  • endometrial CA
  • hepatic tumor, benign
  • hepatic tumor, malignant
  • hepatic disease, active
  • cholestatic jaundice history, oral contraceptive-associated
  • cholestatic jaundice history, pregnancy-associated
  • nephrotic syndrome
  • hemodialysis
  • peritoneal dialysis
  • thrombophlebitis
  • thrombophlebitis history
  • thromboembolism
  • thromboembolism history
  • major surgery with prolonged immobilization
  • smokers >35 yo
  • heavy smokers
  • valvular heart disease, thrombogenic
  • rhythm heart disease, thrombogenic
  • CAD
  • cerebrovascular disease
  • thrombophilia, acquired
  • thrombophilia, hereditary
  • systolic BP >160 or diastolic BP >100, persistent
  • HTN with vascular disease
  • diabetes mellitus with vascular disease
  • migraine with aura
  • vaginal bleeding, undiagnosed
  • SLE antibody, positive or unknown
  • caution: hepatic impairment
  • caution: renal disease
  • caution: HTN
  • caution: hyperlipidemia
  • caution: diabetes mellitus
  • caution: breast CA history
  • caution: inflammatory bowel disease
  • caution: gallbladder disease
  • caution: sensitivity to fluid retention
  • caution: depression history
  • caution: vomiting
  • caution: diarrhea
  • caution: obesity
  • caution: angioedema, hereditary
  • caution: smoking habit change

Drug Interactions .

Overview

ethinyl estradiol (contraceptive)

estrogen

Interaction Characteristics:
  • CYP1A2 substrate
  • CYP2C8 substrate
  • CYP2C9 substrate
  • CYP2C19 substrate
  • CYP3A4 substrate
  • SULT1E1 substrate
  • UGT1A1 substrate
  • P-gp substrate
  • CYP1A2 inhibitor, moderate
  • CYP2C19 inhibitor, weak
  • CYP2D6 inhibitor, weak
  • CYP3A4 inhibitor, weak
  • CYP2C8 inducer, weak
  • UGT1A4 inducer
  • affected by altered gastrointestinal motility
  • binds to anion exchange resin/polymer
  • binds to encapsulating agent
  • binds to polyvalent cations
  • estrogen
  • hyperglycemic effects
  • hypertensive effects
  • interferes w/ ACTH analog test
  • thrombogenic effects
  • thyroid hormone synthesis/metabolism effects

norgestrel (contraceptive)

progestogen

Interaction Characteristics:
  • CYP3A4 substrate
  • affected by altered gastrointestinal motility
  • binds to anion exchange resin/polymer
  • binds to encapsulating agent
  • hyperglycemic effects
  • progesterone agonist
  • thrombogenic effects

Contraindicated

  • cisapride
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cisapride
    1 interaction

    Contraindicated

    ethinyl estradiol (contraceptive) + cisapride

    contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • fezolinetant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fezolinetant
    1 interaction

    Contraindicated

    ethinyl estradiol (contraceptive) + fezolinetant

    contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metabolism inhibited)

  • thioridazine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    thioridazine
    1 interaction

    Contraindicated

    ethinyl estradiol (contraceptive) + thioridazine

    contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • tranexamic acid
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tranexamic acid
    2 interactions

    Contraindicated

    ethinyl estradiol (contraceptive) + tranexamic acid

    contraindicated if oral tranexamic acid use; otherwise, avoid combo: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + tranexamic acid

    contraindicated if oral tranexamic acid use; otherwise, avoid combo: combo may incr. risk of thromboembolism (additive effects)

Avoid/Use Alternative

  • acitretin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    acitretin
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + acitretin

    PROGESTOGEN-ONLY CONTRACEPTION: avoid combo; COMBINED CONTRACEPTION: must use 2 effective contraceptive methods at least 1mo before, during and at least 3y after acitretin tx: combo may decr. contraceptive efficacy (mechanism unknown)

  • albendazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    albendazole
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + albendazole

    use additional non-hormonal or alternative contraception during and x28 days after albendazole tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism possibly induced)

  • alosetron
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    alosetron
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + alosetron

    use alternative: combo may incr. alosetron levels, risk of adverse effects (hepatic metabolism inhibited)

  • alprazolam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    alprazolam
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + alprazolam

    use alternative or monitor respiratory rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • anastrozole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    anastrozole
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + anastrozole

    avoid combo: combo may decr. anastrozole efficacy (antagonistic effects)

  • apalutamide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    apalutamide
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + apalutamide

    use additional non-hormonal or alternative contraception during and x28 days after apalutamide tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, P-gp-mediated transport induced, UGT possibly induced)

    norgestrel (contraceptive) + apalutamide

    use additional non-hormonal or alternative contraception during and x28 days after apalutamide tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • aprepitant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    aprepitant
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + aprepitant

    use additional non-hormonal or alternative contraception during and x28 days after aprepitant tx; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

    norgestrel (contraceptive) + aprepitant

    use additional non-hormonal or alternative contraception during and x28 days after aprepitant tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • armodafinil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    armodafinil
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + armodafinil

    use additional non-hormonal or alternative contraception during and x1mo after armodafinil tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

    norgestrel (contraceptive) + armodafinil

    use additional non-hormonal or alternative contraception during and x1mo after armodafinil tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • artemether/lumefantrine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    artemether/ lumefantrine
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + artemether/ lumefantrine

    use additional non-hormonal or alternative contraception during and x28 days after artemether/lumefantrine tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + artemether/ lumefantrine

    use additional non-hormonal or alternative contraception during and x28 days after artemether/lumefantrine tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • atazanavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    atazanavir
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + atazanavir

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose at least 35 mcg/day; ATAZANAVIR W/ RITONAVIR: use additional non-hormonal or alternative contraception if ethinyl estradiol dose <35 mcg/day (induction predominates); ATAZANAVIR W/O RITONAVIR: avoid combo if ethinyl estradiol dose at least 30 mcg/day (inhibition predominates); ATAZANAVIR W/ COBICISTAT: consider additional non-hormonal or alternative contraception (effects unknown): combo may incr. or decr. ethinyl estradiol levels, incr. risk of thromboembolism, other adverse effects or decr. hormonal contraceptive efficacy (hepatic metabolism altered, UGT inhibited)

    norgestrel (contraceptive) + atazanavir

    use additional non-hormonal or alternative contraception during and x28 days after atazanavir tx; monitor thrombosis s/sx: combo may incr. or decr. norgestrel levels, incr. risk of thromboembolism, other adverse effects or decr. contraceptive efficacy (hepatic metabolism possibly altered)

  • avapritinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    avapritinib
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + avapritinib

    monitor bleeding or thrombosis s/sx, especially if ethinyl estradiol dose >20 mcg; if possible, use alternative contraception: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects; may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited; mechanism unknown)

  • bazedoxifene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bazedoxifene
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + bazedoxifene

    avoid combo: combo may alter efficacy of both drugs, incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, antagonistic effects)

    Monitor/Modify Tx

    norgestrel (contraceptive) + bazedoxifene

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • belzutifan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    belzutifan
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + belzutifan

    use additional non-hormonal or alternative contraception during and x28 days after belzutifan tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + belzutifan

    use additional non-hormonal or alternative contraception during and x28 days after belzutifan tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • bendamustine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bendamustine
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + bendamustine

    consider alternatives: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • bexarotene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bexarotene
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + bexarotene

    use 2 forms of contraception, incl. one non-hormonal, x1mo before, during and x1mo after bexarotene tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + bexarotene

    use 2 forms of contraception, incl. one non-hormonal, x1mo before, during and x1mo after bexarotene tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • bosentan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bosentan
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + bosentan

    use additional non-hormonal or alternative contraception during and x28 days after bosentan tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + bosentan

    use additional non-hormonal or alternative contraception during and x28 days after bosentan tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • brigatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    brigatinib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + brigatinib

    use additional non-hormonal or alternative contraception during and x28 days after brigatinib tx; monitor BP, HR: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + brigatinib

    use additional non-hormonal or alternative contraception during and x28 days after brigatinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • butalbital
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    butalbital
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + butalbital

    use additional non-hormonal or alternative contraception during and x28 days after butalbital tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT induced)

    norgestrel (contraceptive) + butalbital

    use additional non-hormonal or alternative contraception during and x28 days after butalbital tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • cannabis
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cannabis
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + cannabis

    monitor BP; use additional non-hormonal or alternative contraception during and x28 days after smoked cannabis use: combo may incr. risk of HTN; combo with smoked cannabis may decr. ethinyl estradiol levels, contraceptive efficacy (additive effects; hepatic metabolism induced, smoked cannabis produces polycyclic aromatic hydrocarbons)

  • carbamazepine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    carbamazepine
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + carbamazepine

    use additional non-hormonal or alternative contraception during and x28 days after carbamazepine tx; monitor carbamazepine levels: combo may incr. carbamazepine levels, risk of adverse effects; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism induced, UGT induced, P-gp-mediated transport induced)

    norgestrel (contraceptive) + carbamazepine

    use additional non-hormonal or alternative contraception during and x28 days after carbamazepine tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • carfilzomib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    carfilzomib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + carfilzomib

    consider non-hormonal contraceptive alternative; otherwise, monitor thrombosis s/sx, BP: combo may incr. risk of thromboembolism, HTN (additive effects)

    norgestrel (contraceptive) + carfilzomib

    consider non-hormonal contraceptive alternative; otherwise, monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • cenobamate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cenobamate
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + cenobamate

    use additional non-hormonal or alternative contraception during and x28 days after cenobamate tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + cenobamate

    use additional non-hormonal or alternative contraception during and x28 days after cenobamate tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • clobazam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    clobazam
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + clobazam

    use additional non-hormonal or alternative contraception during and x28 days after clobazam tx; monitor respiratory rate: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. clobazam and active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

    norgestrel (contraceptive) + clobazam

    use additional non-hormonal or alternative contraception during and x28 days after clobazam tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • clomiphene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    clomiphene
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + clomiphene

    avoid combo: combo may alter efficacy of both drugs, incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, antagonistic effects)

  • codeine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    codeine
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + codeine

    use alternative or monitor respiratory rate, withdrawal sx: combo may incr. codeine, alter active metabolite morphine levels, incr. risk of CNS and respiratory depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may alter production of active metabolite morphine)

  • colchicine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    colchicine
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + colchicine

    CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT or FMF: use alternative or consider decr. colchicine dose during and x14 days after ethinyl estradiol use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited)

  • dabrafenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dabrafenib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + dabrafenib

    use additional non-hormonal or alternative contraception during and x28 days after dabrafenib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + dabrafenib

    use additional non-hormonal or alternative contraception during and x28 days after dabrafenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • danshen
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    danshen
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + danshen

    use additional non-hormonal or alternative contraception during and x28 days after danshen tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

    norgestrel (contraceptive) + danshen

    use additional non-hormonal or alternative contraception during and x28 days after danshen tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • darolutamide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    darolutamide
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + darolutamide

    use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + darolutamide

    use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • darunavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    darunavir
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + darunavir

    use additional non-hormonal or alternative contraception during and x28 days after darunavir tx; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

    norgestrel (contraceptive) + darunavir

    use additional non-hormonal or alternative contraception during and x28 days after darunavir tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • deferasirox
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    deferasirox
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + deferasirox

    use additional non-hormonal or alternative contraception during and x28 days after deferasirox tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + deferasirox

    use additional non-hormonal or alternative contraception during and x28 days after deferasirox tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • desogestrel (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    desogestrel (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + desogestrel (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • dexamethasone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dexamethasone
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + dexamethasone

    use additional non-hormonal or alternative contraception during and x28 days after dexamethasone tx; monitor BP, thrombosis s/sx, especially if multiple myeloma use: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN, thromboembolism (hepatic metabolism induced; additive effects)

    norgestrel (contraceptive) + dexamethasone

    use additional non-hormonal or alternative contraception during and x28 days after dexamethasone tx; monitor thrombosis s/sx, especially w/ concomitant estrogen or multiple myeloma use: combo may decr. norgestrel levels, contraceptive efficacy; may incr. risk of thromboembolism (hepatic metabolism induced; additive effects)

  • dicloxacillin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dicloxacillin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + dicloxacillin

    use additional non-hormonal or alternative contraception during and x28 days after dicloxacillin tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

    norgestrel (contraceptive) + dicloxacillin

    use additional non-hormonal or alternative contraception during and x28 days after dicloxacillin tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • dienogest (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dienogest (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + dienogest (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • dihydrocodeine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dihydrocodeine
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + dihydrocodeine

    use alternative or monitor respiratory rate, withdrawal sx: combo may incr. dihydrocodeine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite dihydromorphine levels, efficacy (hepatic metabolism inhibited, decr. conversion to dihydromorphine)

  • drospirenone (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    drospirenone (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + drospirenone (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • drospirenone (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    drospirenone (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    norgestrel (contraceptive) + drospirenone (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + drospirenone (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • dulaglutide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dulaglutide
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + dulaglutide

    consider alternative w/ oral ethinyl estradiol; otherwise, monitor glucose: combo may decr. peak ethinyl estradiol levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

    norgestrel (contraceptive) + dulaglutide

    consider alternative: combo may decr. peak norgestrel levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

  • echinacea
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    echinacea
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + echinacea

    use additional non-hormonal or alternative contraception during and x28 days after echinacea tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + echinacea

    use additional non-hormonal or alternative contraception during and x28 days after echinacea tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • efavirenz
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    efavirenz
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + efavirenz

    use additional non-hormonal or alternative contraception during and x28 days after efavirenz tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT induced, P-gp-mediated transport induced)

    norgestrel (contraceptive) + efavirenz

    use additional non-hormonal or alternative contraception during and x28 days after efavirenz tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • elafibranor
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    elafibranor
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + elafibranor

    use additional non-hormonal or alternative contraception during and x28 days after elafibranor tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + elafibranor

    use additional non-hormonal or alternative contraception during and x28 days after elafibranor tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • elagolix
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    elagolix
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + elagolix

    use alternative non-hormonal contraception during and x28 days after elagolix tx: combo may decr. elagolix efficacy; may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (antagonistic effects; mechanism unknown)

    norgestrel (contraceptive) + elagolix

    use alternative non-hormonal contraception during and x28 days after elagolix tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • eliglustat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    eliglustat
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + eliglustat

    CYP2D6 EM: monitor ECG; if Child-Pugh Class A, decr. eliglustat dose to 84 mg qd; CYP2D6 IM: monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • elvitegravir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    elvitegravir
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + elvitegravir

    use additional non-hormonal or alternative contraception during and x28 days after elvitegravir tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

  • enasidenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    enasidenib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + enasidenib

    use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + enasidenib

    use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • encorafenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    encorafenib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + encorafenib

    use additional non-hormonal or alternative contraception during and x28 days after encorafenib tx; monitor ECG: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    norgestrel (contraceptive) + encorafenib

    use additional non-hormonal or alternative contraception during and x28 days after encorafenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • enzalutamide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    enzalutamide
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + enzalutamide

    use additional non-hormonal or alternative contraception during and x28 days after enzalutamide tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + enzalutamide

    use additional non-hormonal or alternative contraception during and x28 days after enzalutamide tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • epinephrine inhaled
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    epinephrine inhaled
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + epinephrine inhaled

    avoid combo: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • eslicarbazepine acetate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    eslicarbazepine acetate
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + eslicarbazepine acetate

    use additional non-hormonal or alternative contraception during and x28 days after eslicarbazepine acetate tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + eslicarbazepine acetate

    use additional non-hormonal or alternative contraception during and x28 days after eslicarbazepine acetate tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • estetrol (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    estetrol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + estetrol (contraceptive)

    avoid combo: combo may incr. risk of HTN, thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy)

  • estradiol (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + estradiol (contraceptive)

    avoid combo: combo may incr. risk of HTN, thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy)

  • estradiol (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    estradiol (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + estradiol (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    norgestrel (contraceptive) + estradiol (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • estrogens, conjugated (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    estrogens, conjugated (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + estrogens, conjugated (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    norgestrel (contraceptive) + estrogens, conjugated (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • estrogens, esterified (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    estrogens, esterified (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + estrogens, esterified (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    norgestrel (contraceptive) + estrogens, esterified (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • ethinyl estradiol (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + ethinyl estradiol (contraceptive)

    avoid combo: combo may incr. risk of HTN, thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy)

  • ethinyl estradiol (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ethinyl estradiol (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + ethinyl estradiol (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    norgestrel (contraceptive) + ethinyl estradiol (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • ethynodiol (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ethynodiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + ethynodiol (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • etonogestrel (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    etonogestrel (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + etonogestrel (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • etravirine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    etravirine
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + etravirine

    use additional non-hormonal or alternative contraception during and x28 days after etravirine tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • exemestane
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    exemestane
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + exemestane

    avoid combo: combo may decr. exemestane efficacy (antagonistic effects)

  • felbamate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    felbamate
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + felbamate

    use additional non-hormonal or alternative contraception during and x28 days after felbamate tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + felbamate

    use additional non-hormonal or alternative contraception during and x28 days after felbamate tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • fexinidazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fexinidazole
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + fexinidazole

    use additional non-hormonal or alternative contraception during and x28 days after fexinidazole tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may decr. fexinidazole active metabolite levels, efficacy (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites)

    norgestrel (contraceptive) + fexinidazole

    use additional non-hormonal or alternative contraception during and x28 days after fexinidazole tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • fitusiran
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fitusiran
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + fitusiran

    use alternative non-hormonal contraception: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + fitusiran

    use alternative non-hormonal contraception: combo may incr. risk of thromboembolism (additive effects)

  • fosamprenavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fosamprenavir
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + fosamprenavir

    use additional non-hormonal or alternative contraception during and x28 days after fosamprenavir tx; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. levels, efficacy of both drugs; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects; may incr. hepatic transaminases (hepatic metabolism induced; hepatic metabolism inhibited; additive effects)

    norgestrel (contraceptive) + fosamprenavir

    use additional non-hormonal or alternative contraception during and x28 days after fosamprenavir tx: combo may decr. levels, efficacy of both drugs; combo of fosamprenavir, ritonavir and hormonal contraceptives may incr. hepatic transaminases (hepatic metabolism induced)

  • fosaprepitant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fosaprepitant
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + fosaprepitant

    use additional non-hormonal or alternative contraception during and x28 days after fosaprepitant tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + fosaprepitant

    use additional non-hormonal or alternative contraception during and x28 days after fosaprepitant tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • fosphenytoin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fosphenytoin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + fosphenytoin

    use additional non-hormonal or alternative contraception during and x28 days after fosphenytoin tx; monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism induced, P-gp-mediated transport induced, UGT induced)

    norgestrel (contraceptive) + fosphenytoin

    use additional non-hormonal or alternative contraception during and x28 days after fosphenytoin tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • furosemide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    furosemide
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + furosemide

    use alternative or monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • garlic
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    garlic
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + garlic

    use additional non-hormonal or alternative contraception during and x28 days after supplemental garlic tx; dietary intake OK: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + garlic

    use additional non-hormonal or alternative contraception during and x28 days after supplemental garlic tx; dietary intake OK: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • ginkgo
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ginkgo
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + ginkgo

    use additional non-hormonal or alternative contraception during and x28 days after ginkgo tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + ginkgo

    use additional non-hormonal or alternative contraception during and x28 days after ginkgo tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • ginseng, Asian
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ginseng, Asian
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + ginseng, Asian

    use additional non-hormonal or alternative contraception during and x28 days after Asian ginseng tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may interfere with hormone tx (hepatic metabolism induced; Panax ginseng may have estrogenic effects)

    norgestrel (contraceptive) + ginseng, Asian

    use additional non-hormonal or alternative contraception during and x28 days after Asian ginseng tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • glecaprevir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    glecaprevir
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + glecaprevir

    avoid combo if ethinyl estradiol dose >20 mcg/day: combo may incr. risk of ALT elevation (additive effects)

  • glycerol phenylbutyrate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    glycerol phenylbutyrate
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + glycerol phenylbutyrate

    use additional non-hormonal or alternative contraception during and x28 days after glycerol phenylbutyrate tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + glycerol phenylbutyrate

    use additional non-hormonal or alternative contraception during and x28 days after glycerol phenylbutyrate tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • grape
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    grape
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + grape

    use additional non-hormonal or alternative contraception during and x28 days after grape tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

  • griseofulvin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    griseofulvin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + griseofulvin

    use additional non-hormonal or alternative contraception during and x28 days after griseofulvin tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + griseofulvin

    use additional non-hormonal or alternative contraception during and x28 days after griseofulvin tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • hydrocodone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    hydrocodone
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + hydrocodone

    use alternative or monitor respiratory rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ivosidenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ivosidenib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + ivosidenib

    use alternative non-hormonal contraception during and x28 days after ivosidenib tx; monitor ECG: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    norgestrel (contraceptive) + ivosidenib

    use additional non-hormonal or alternative contraception during and x28 days after ivosidenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • letrozole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    letrozole
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + letrozole

    avoid combo: combo may decr. letrozole efficacy (antagonistic effects)

  • levonorgestrel (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    levonorgestrel (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + levonorgestrel (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • levonorgestrel (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    levonorgestrel (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    norgestrel (contraceptive) + levonorgestrel (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + levonorgestrel (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • liraglutide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    liraglutide
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + liraglutide

    consider alternative w/ oral ethinyl estradiol; otherwise, monitor glucose in type 2 diabetes mellitus pts: combo may decr. peak ethinyl estradiol levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

    norgestrel (contraceptive) + liraglutide

    consider alternative: combo may decr. peak norgestrel levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

  • lixisenatide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lixisenatide
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + lixisenatide

    consider alternative or monitor glucose; give oral ethinyl estradiol at least 1h before or at least 11h after lixisenatide: combo may decr. peak ethinyl estradiol levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

    norgestrel (contraceptive) + lixisenatide

    consider alternative or monitor glucose; give norgestrel at least 1h before or at least 11h after lixisenatide: combo may decr. peak norgestrel levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

  • lopinavir/ritonavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lopinavir/ ritonavir
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + lopinavir/ ritonavir

    use additional non-hormonal or alternative contraception during and x28 days after lopinavir/ritonavir tx; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, UGT inhibited)

    norgestrel (contraceptive) + lopinavir/ ritonavir

    use additional non-hormonal or alternative contraception during and x28 days after lopinavir/ritonavir tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • lorlatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lorlatinib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + lorlatinib

    use additional non-hormonal or alternative contraception during and x28 days after lorlatinib tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN (hepatic metabolism induced, P-gp-mediated transport induced, UGT induced; additive effects)

    norgestrel (contraceptive) + lorlatinib

    use additional non-hormonal or alternative contraception during and x28 days after lorlatinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • lumacaftor/ivacaftor
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lumacaftor/ ivacaftor
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + lumacaftor/ ivacaftor

    use additional non-hormonal or alternative contraception during and x28 days after lumacaftor/ivacaftor tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN (hepatic metabolism induced, P-gp-mediated transport possibly induced; additive effects)

    norgestrel (contraceptive) + lumacaftor/ ivacaftor

    use additional non-hormonal or alternative contraception during and x28 days after lumacaftor/ivacaftor tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • mavacamten
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    mavacamten
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + mavacamten

    ALL FORMS: monitor cardiac fxn, incl. LVEF; if patient stable on ethinyl estradiol, start mavacamten at 5 mg qd; if adding short-term (<1wk) ethinyl estradiol to mavacamten, hold mavacamten until ethinyl estradiol D/C; if adding longer-term (>1wk) ethinyl estradiol, decr. mavacamten dose per pkg insert; do not start ethinyl estradiol if on mavacamten 2.5 mg qd; WITH NORETHINDRONE: use OK; WITH OTHER PROGESTOGENS: use additional non-hormonal or alternative contraception during and x4mo after mavacamten: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    norgestrel (contraceptive) + mavacamten

    use additional non-hormonal or alternative contraception during and x4mo after mavacamten tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • medroxyprogesterone (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    medroxyprogesterone (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + medroxyprogesterone (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • medroxyprogesterone (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    medroxyprogesterone (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    norgestrel (contraceptive) + medroxyprogesterone (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + medroxyprogesterone (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • megestrol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    megestrol
    2 interactions

    Avoid/Use Alternative

    norgestrel (contraceptive) + megestrol

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + megestrol

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • meperidine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    meperidine
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + meperidine

    use alternative or monitor respiratory rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • meropenem
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    meropenem
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + meropenem

    use additional non-hormonal or alternative contraception during and x28 days after meropenem tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism possibly induced, P-gp-mediated transport possibly induced)

    norgestrel (contraceptive) + meropenem

    use additional non-hormonal or alternative contraception during and x28 days after meropenem tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

  • methadone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    methadone
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + methadone

    use alternative or monitor respiratory rate, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • midodrine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    midodrine
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + midodrine

    use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

  • mifepristone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    mifepristone
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + mifepristone

    use alternative non-hormonal contraception during and x1mo after daily mifepristone use: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

    norgestrel (contraceptive) + mifepristone

    use alternative non-hormonal contraception during and x1mo after daily mifepristone use: combo may decr. hormonal contraceptive efficacy (antagonistic effects)

  • mitapivat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    mitapivat
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + mitapivat

    use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT possibly induced)

    norgestrel (contraceptive) + mitapivat

    use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • mitotane
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    mitotane
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + mitotane

    use additional non-hormonal or alternative contraception during and x28 days after mitotane tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + mitotane

    use additional non-hormonal or alternative contraception during and x28 days after mitotane tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • mobocertinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    mobocertinib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + mobocertinib

    monitor ECG; use additional non-hormonal or alternative contraception during and x28 days after mobocertinib tx: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    norgestrel (contraceptive) + mobocertinib

    use additional non-hormonal or alternative contraception during and x28 days after mobocertinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • modafinil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    modafinil
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + modafinil

    use additional non-hormonal or alternative contraception during and x1mo after modafinil tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

    norgestrel (contraceptive) + modafinil

    use additional non-hormonal or alternative contraception during and x1mo after modafinil tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • nafcillin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nafcillin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + nafcillin

    use additional non-hormonal or alternative contraception during and x28 days after nafcillin tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + nafcillin

    use additional non-hormonal or alternative contraception during and x28 days after nafcillin tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • nelfinavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nelfinavir
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + nelfinavir

    use additional non-hormonal or alternative contraception during and x28 days after nelfinavir tx; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

    norgestrel (contraceptive) + nelfinavir

    use additional non-hormonal or alternative contraception during and x28 days after nelfinavir tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • nevirapine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nevirapine
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + nevirapine

    use additional non-hormonal or alternative contraception during and x28 days after nevirapine tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + nevirapine

    use additional non-hormonal or alternative contraception during and x28 days after nevirapine tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • nirogacestat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nirogacestat
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + nirogacestat

    use additional non-hormonal or alternative contraception during and x28 days after nirogacestat tx; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. or decr. ethinyl estradiol levels, incr. risk of thromboembolism, other adverse effects or decr. hormonal contraceptive efficacy (hepatic metabolism inhibited, hepatic metabolism possibly induced)

  • norelgestromin (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    norelgestromin (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + norelgestromin (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • norethindrone (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    norethindrone (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + norethindrone (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • norethindrone (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    norethindrone (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    norgestrel (contraceptive) + norethindrone (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + norethindrone (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • norgestimate (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    norgestimate (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + norgestimate (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • norgestrel (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    norgestrel (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + norgestrel (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • olutasidenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    olutasidenib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + olutasidenib

    use additional non-hormonal or alternative contraception during and x28 days after olutasidenib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism possibly induced)

    norgestrel (contraceptive) + olutasidenib

    use additional non-hormonal or alternative contraception during and x28 days after olutasidenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

  • omaveloxolone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    omaveloxolone
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + omaveloxolone

    use additional non-hormonal or alternative contraception during and x28 days after omaveloxolone tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + omaveloxolone

    use additional non-hormonal or alternative contraception during and x28 days after omaveloxolone tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • orforglipron
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    orforglipron
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + orforglipron

    use alternative non-oral hormonal contraceptive or additional non-hormonal contraceptive x30 days after orforglipron start and x30 days after each dose incr.: combo may decr. peak ethinyl estradiol levels, contraceptive efficacy (absorption delayed, possibly decreased)

    norgestrel (contraceptive) + orforglipron

    use alternative non-oral hormonal contraceptive or additional non-hormonal contraceptive x30 days after orforglipron start and x30 days after each dose incr.: combo may decr. peak norgestrel levels, contraceptive efficacy (absorption delayed, possibly decreased)

  • ospemifene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ospemifene
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + ospemifene

    avoid combo: combo may alter efficacy of both drugs, incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, antagonistic effects)

    Monitor/Modify Tx

    norgestrel (contraceptive) + ospemifene

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • oxcarbazepine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    oxcarbazepine
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + oxcarbazepine

    use additional non-hormonal or alternative contraception during and x28 days after oxcarbazepine tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT induced, P-gp-mediated transport possibly induced)

    norgestrel (contraceptive) + oxcarbazepine

    use additional non-hormonal or alternative contraception during and x28 days after oxcarbazepine tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • oxycodone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    oxycodone
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + oxycodone

    use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • pacritinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pacritinib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pacritinib

    use additional non-hormonal or alternative contraception during and x30 days after pacritinib tx; monitor ECG, CBC, bleeding or thrombosis s/sx: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + pacritinib

    use additional non-hormonal or alternative contraception during and x30 days after pacritinib tx; monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may decr. norgestrel levels, contraceptive efficacy; may incr. risk of thromboembolism (hepatic metabolism induced; additive effects)

  • pentobarbital
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pentobarbital
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pentobarbital

    use additional non-hormonal or alternative contraception during and x28 days after pentobarbital tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT induced)

    norgestrel (contraceptive) + pentobarbital

    use additional non-hormonal or alternative contraception during and x28 days after pentobarbital tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • perampanel
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    perampanel
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + perampanel

    if on perampanel 12 mg/day, use additional non-hormonal or alternative contraception during and x28 days after perampanel tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + perampanel

    if on perampanel 12 mg/day, use additional non-hormonal or alternative contraception during and x28 days after perampanel tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • pexidartinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pexidartinib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pexidartinib

    use additional non-hormonal or alternative contraception during and x1mo after pexidartinib tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may incr. risk of HTN (hepatic metabolism induced; hepatic metabolism inhibited; additive effects)

    norgestrel (contraceptive) + pexidartinib

    use additional non-hormonal or alternative contraception during and x1mo after pexidartinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • phenobarbital
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phenobarbital
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + phenobarbital

    use additional non-hormonal or alternative contraception during and x28 days after phenobarbital tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT induced, P-gp-mediated transport possibly induced)

    norgestrel (contraceptive) + phenobarbital

    use additional non-hormonal or alternative contraception during and x28 days after phenobarbital tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • phenytoin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phenytoin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + phenytoin

    use additional non-hormonal or alternative contraception during and x28 days after phenytoin tx; monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism induced, UGT induced, P-gp-mediated transport induced)

    norgestrel (contraceptive) + phenytoin

    use additional non-hormonal or alternative contraception during and x28 days after phenytoin tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • pibrentasvir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pibrentasvir
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pibrentasvir

    avoid combo if ethinyl estradiol dose >20 mcg/day: combo may incr. risk of ALT elevation (additive effects)

  • pimozide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pimozide
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pimozide

    use alternative or monitor ECG: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • pioglitazone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pioglitazone
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pioglitazone

    use additional non-hormonal or alternative contraception during and x28 days after pioglitazone tx; monitor glucose: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (hepatic metabolism induced; antagonistic effects)

    norgestrel (contraceptive) + pioglitazone

    use additional non-hormonal or alternative contraception during and x28 days after pioglitazone tx; monitor glucose: combo may decr. norgestrel levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (hepatic metabolism induced; antagonistic effects)

  • pirfenidone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pirfenidone
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pirfenidone

    avoid combo if also combined w/ mod-strong CYP2C9, CYP2C19, CYP2D6, or CYP2E1 inhibitor; otherwise, consider alternative or decr. pirfenidone dose to 534 mg tid: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metabolism inhibited)

  • pitolisant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pitolisant
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pitolisant

    use additional non-hormonal or alternative contraception during and x28 days after pitolisant tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + pitolisant

    use additional non-hormonal or alternative contraception during and x28 days after pitolisant tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • posaconazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    posaconazole
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + posaconazole

    use alternative or monitor breakthrough fungal infection, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects; may decr. posaconazole levels, efficacy (hepatic metabolism inhibited; UGT possibly induced)

  • pralsetinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pralsetinib
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + pralsetinib

    if also combined w/ P-gp inhibitor, use alternative or monitor BP, consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd; otherwise, monitor BP, consider monitoring ECG, electrolytes: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • prednisone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    prednisone
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + prednisone

    use additional non-hormonal or alternative contraception during and x28 days after prednisone tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

    norgestrel (contraceptive) + prednisone

    use additional non-hormonal or alternative contraception during and x28 days after prednisone tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • primidone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    primidone
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + primidone

    use additional non-hormonal or alternative contraception during and x28 days after primidone tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, P-gp-mediated transport possibly induced, UGT induced)

    norgestrel (contraceptive) + primidone

    use additional non-hormonal or alternative contraception during and x28 days after primidone tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • progesterone (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    progesterone (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    norgestrel (contraceptive) + progesterone (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + progesterone (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • progesterone vaginal (hormone replacement)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    progesterone vaginal (hormone replacement)
    2 interactions

    Avoid/Use Alternative

    norgestrel (contraceptive) + progesterone vaginal (hormone replacement)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + progesterone vaginal (hormone replacement)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • propafenone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    propafenone
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + propafenone

    avoid combo: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

  • raloxifene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    raloxifene
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + raloxifene

    avoid combo: combo may alter efficacy of both drugs, incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, antagonistic effects)

    Monitor/Modify Tx

    norgestrel (contraceptive) + raloxifene

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • relacorilant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    relacorilant
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + relacorilant

    use additional non-hormonal or alternative contraception during and x28 days after relacorilant use; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

  • relugolix
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    relugolix
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + relugolix

    use alternative non-hormonal contraception during and x1wk after relugolix D/C: combo may decr. relugolix efficacy (antagonistic effects)

  • repotrectinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    repotrectinib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + repotrectinib

    use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

    norgestrel (contraceptive) + repotrectinib

    use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • rifabutin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rifabutin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + rifabutin

    use additional non-hormonal or alternative contraception during and x28 days after rifabutin tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT induced, P-gp-mediated transport possibly induced)

    norgestrel (contraceptive) + rifabutin

    use additional non-hormonal or alternative contraception during and x28 days after rifabutin tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • rifampin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rifampin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + rifampin

    use additional non-hormonal or alternative contraception during and x28 days after rifampin tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT induced, P-gp-mediated transport induced)

    norgestrel (contraceptive) + rifampin

    use additional non-hormonal or alternative contraception during and x28 days after rifampin tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • rifapentine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rifapentine
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + rifapentine

    use additional non-hormonal or alternative contraception during and x28 days after rifapentine tx; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced, UGT possibly induced, P-gp-mediated transport possibly induced; UGT inhibited)

    norgestrel (contraceptive) + rifapentine

    use additional non-hormonal or alternative contraception during and x28 days after rifapentine tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • ritonavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ritonavir
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + ritonavir

    FOR ALL INDICATIONS: monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day; FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced, UGT induced; hepatic metabolism inhibited)

    norgestrel (contraceptive) + ritonavir

    FIXED-DOSE COMBO FOR COVID-19 INFECTION: use additional non-hormonal or alternative contraception during nirmatrelvir/ritonavir tx and through one complete menstrual cycle after nirmatrelvir/ritonavir D/C; HIV INFECTION: use additional non-hormonal or alternative contraception during and x28 days after ritonavir tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • romidepsin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    romidepsin
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + romidepsin

    use alternate contraception during and x1mo after romidepsin tx: combo may decr. hormonal contraceptive efficacy (possible antagonistic effects)

  • rufinamide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rufinamide
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + rufinamide

    use additional non-hormonal or alternative contraception during and x28 days after rufinamide tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + rufinamide

    use additional non-hormonal or alternative contraception during and x28 days after rufinamide tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • sarilumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sarilumab
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + sarilumab

    use additional non-hormonal or alternative contraception during and x28 days after sarilumab tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

    norgestrel (contraceptive) + sarilumab

    use additional non-hormonal or alternative contraception during and x28 days after sarilumab tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

  • segesterone (contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    segesterone (contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + segesterone (contraceptive)

    avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • simvastatin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    simvastatin
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + simvastatin

    use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • sotorasib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sotorasib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + sotorasib

    use additional non-hormonal or alternative contraception during and x28 days after sotorasib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + sotorasib

    use additional non-hormonal or alternative contraception during and x28 days after sotorasib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • sparsentan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sparsentan
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + sparsentan

    use additional non-hormonal or alternative contraception during and x28 days after sparsentan tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

  • St. John's wort
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    St. John's wort
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + St. John's wort

    use additional non-hormonal or alternative contraception during and x28 days after St. John's wort tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

    norgestrel (contraceptive) + St. John's wort

    use additional non-hormonal or alternative contraception during and x28 days after St. John's wort tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • stiripentol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    stiripentol
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + stiripentol

    use additional non-hormonal or alternative contraception during and x28 days after stiripentol tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism possibly induced)

    norgestrel (contraceptive) + stiripentol

    use additional non-hormonal or alternative contraception during and x28 days after stiripentol tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

  • sugammadex
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sugammadex
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + sugammadex

    use additional non-hormonal or alternative contraception x7 days after sugammadex use: combo may decr. hormonal contraceptive levels, efficacy (approximately equivalent to one missed OCP dose) (hormonal contraceptives bind to sugammadex)

    norgestrel (contraceptive) + sugammadex

    use additional non-hormonal or alternative contraception x7 days after sugammadex use: combo may decr. hormonal contraceptive levels, efficacy (approximately equivalent to one missed OCP dose) (hormonal contraceptives bind to sugammadex)

  • sunvozertinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sunvozertinib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + sunvozertinib

    use additional non-hormonal or alternative contraception during and x28 days after sunvozertinib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + sunvozertinib

    use additional non-hormonal or alternative contraception during and x28 days after sunvozertinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • suzetrigine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    suzetrigine
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + suzetrigine

    ETHINYL ESTRADIOL IN COMBO W/ NORETHINDRONE or LEVONORGESTREL: use OK; ETHINYL ESTRADIOL IN COMBO W/ OTHER PROGESTOGENS: use additional non-hormonal or alternative contraception during and x28 days after suzetrigine tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + suzetrigine

    use additional non-hormonal or alternative contraception during and x28 days after suzetrigine tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • tamoxifen
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tamoxifen
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tamoxifen

    avoid combo: combo may alter efficacy of both drugs, incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, antagonistic effects)

    Monitor/Modify Tx

    norgestrel (contraceptive) + tamoxifen

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • tazemetostat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tazemetostat
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tazemetostat

    use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + tazemetostat

    use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • tecovirimat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tecovirimat
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tecovirimat

    use additional non-hormonal or alternative contraception during and x28 days after tecovirimat tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + tecovirimat

    use additional non-hormonal or alternative contraception during and x28 days after tecovirimat tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • telotristat ethyl
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    telotristat ethyl
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + telotristat ethyl

    use additional non-hormonal or alternative contraception during and x28 days after telotristat ethyl tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + telotristat ethyl

    use additional non-hormonal or alternative contraception during and x28 days after telotristat ethyl tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • tesamorelin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tesamorelin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tesamorelin

    use additional non-hormonal or alternative contraception during and x28 days after tesamorelin tx: combo may incr. or decr. ethinyl estradiol levels, incr. risk of adverse effects or decr. contraceptive efficacy (hepatic metabolism possibly altered)

    norgestrel (contraceptive) + tesamorelin

    use additional non-hormonal or alternative contraception during and x28 days after tesamorelin tx: combo may incr. or decr. norgestrel levels, incr. risk of adverse effects or decr. contraceptive efficacy (hepatic metabolism possibly altered)

  • tipranavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tipranavir
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tipranavir

    use additional non-hormonal or alternative contraception during and x28 days after tipranavir tx; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced, UGT induced, P-gp-mediated transport induced; hepatic metabolism inhibited)

  • tirzepatide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tirzepatide
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tirzepatide

    monitor glucose if type 2 diabetes mellitus use; use alternative non-oral hormonal contraceptive or additional non-hormonal contraceptive x4wk after tirzepatide tx start and x4wk after each dose incr.: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

    norgestrel (contraceptive) + tirzepatide

    monitor glucose if type 2 diabetes mellitus use; use alternative non-oral hormonal contraceptive or additional non-hormonal contraceptive x4wk after tirzepatide tx start and x4wk after each dose incr.: combo may decr. peak norgestrel levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

  • tizanidine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tizanidine
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tizanidine

    use alternative or monitor BP, HR: combo may incr. tizanidine levels, risk of hypotension (including orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • tocilizumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tocilizumab
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tocilizumab

    use additional non-hormonal or alternative contraception during and x28 days after tocilizumab tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

    norgestrel (contraceptive) + tocilizumab

    use additional non-hormonal or alternative contraception during and x28 days after tocilizumab tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

  • topiramate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    topiramate
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + topiramate

    use additional non-hormonal or alternative contraception during and x28 days after topiramate tx, especially w/ topiramate doses >200 mg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + topiramate

    use additional non-hormonal or alternative contraception during and x28 days after topiramate tx, especially w/ topiramate doses >200 mg/day: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • toremifene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    toremifene
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + toremifene

    avoid combo: combo may alter efficacy of both drugs, incr. risk of thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, antagonistic effects)

    Monitor/Modify Tx

    norgestrel (contraceptive) + toremifene

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

  • tovorafenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tovorafenib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tovorafenib

    use additional non-hormonal or alternative contraception during and x28 days after tovorafenib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + tovorafenib

    use additional non-hormonal or alternative contraception during and x28 days after tovorafenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • tramadol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tramadol
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + tramadol

    use alternative or monitor respiratory rate, ECG, withdrawal sx: combo may incr. tramadol levels, risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • turmeric
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    turmeric
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + turmeric

    use additional non-hormonal or alternative contraception during and x28 days after oral turmeric tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (P-gp-mediated transport induced)

  • ulipristal (post-coital contraceptive)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ulipristal (post-coital contraceptive)
    1 interaction

    Avoid/Use Alternative

    norgestrel (contraceptive) + ulipristal (post-coital contraceptive)

    initiate or resume norgestrel no sooner than 5 days after ulipristal tx; use additional non-hormonal contraception until next menses: combo may decr. efficacy of both drugs (antagonistic effects)

  • vaborbactam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vaborbactam
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + vaborbactam

    use additional non-hormonal or alternative contraception during and x28 days after vaborbactam tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism possibly induced, P-gp-mediated transport possibly induced)

    norgestrel (contraceptive) + vaborbactam

    use additional non-hormonal or alternative contraception during and x28 days after vaborbactam tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

  • vaccinia immune globulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vaccinia immune globulin
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + vaccinia immune globulin

    use alternative or monitor thrombosis s/sx; use lowest vaccinia immune globulin concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + vaccinia immune globulin

    use alternative or monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest vaccinia immune globulin concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • valproic acid
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    valproic acid
    1 interaction

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + valproic acid

    use additional non-hormonal or alternative contraception during and x28 days after valproic acid tx; monitor valproic acid levels: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may decr. valproic acid levels, efficacy (UGT induced, hepatic metabolism induced)

  • vamorolone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vamorolone
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + vamorolone

    use additional non-hormonal or alternative contraception during and x28 days after vamorolone tx; monitor BP, thrombosis s/sx: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN, thromboembolism (hepatic metabolism possibly induced; additive effects)

    norgestrel (contraceptive) + vamorolone

    use additional non-hormonal or alternative contraception during and x28 days after vamorolone tx; monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may decr. norgestrel levels, contraceptive efficacy; may incr. risk of thromboembolism (hepatic metabolism possibly induced; additive effects)

  • vemurafenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vemurafenib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + vemurafenib

    use additional non-hormonal or alternative contraception during and x28 days after vemurafenib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

    norgestrel (contraceptive) + vemurafenib

    use additional non-hormonal or alternative contraception during and x28 days after vemurafenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • vinblastine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vinblastine
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + vinblastine

    use additional non-hormonal or alternative contraception during and x28 days after vinblastine tx; monitor CBC: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

    norgestrel (contraceptive) + vinblastine

    use additional non-hormonal or alternative contraception during and x28 days after vinblastine tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

  • vorasidenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vorasidenib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + vorasidenib

    use alternative: combo may incr. vorasidenib levels, risk of adverse effects; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

    norgestrel (contraceptive) + vorasidenib

    use additional non-hormonal or alternative contraception during and x28 days after vorasidenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

  • zanubrutinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    zanubrutinib
    2 interactions

    Avoid/Use Alternative

    ethinyl estradiol (contraceptive) + zanubrutinib

    monitor CBC; use additional non-hormonal or alternative contraception during and x28 days after zanubrutinib tx: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

    norgestrel (contraceptive) + zanubrutinib

    use additional non-hormonal or alternative contraception during and x28 days after zanubrutinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

Monitor/Modify Tx

  • abemaciclib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    abemaciclib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + abemaciclib

    monitor CBC, thrombosis s/sx: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thromboembolism, other adverse effects (hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + abemaciclib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • abiraterone acetate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + abiraterone acetate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • abrocitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    abrocitinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + abrocitinib

    monitor thrombosis s/sx: combo may incr. abrocitinib and active metabolite levels, risk of serious infection, thromboembolism, other adverse effects (hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + abrocitinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • acalabrutinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    acalabrutinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + acalabrutinib

    monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • acarbose
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    acarbose
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + acarbose

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + acarbose

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • acebutolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + acebutolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • acetaminophen
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    acetaminophen
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + acetaminophen

    monitor thrombosis s/sx: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (mechanism unknown)

  • adagrasib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    adagrasib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + adagrasib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • aflibercept
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    aflibercept
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + aflibercept

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + aflibercept

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • albuterol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    albuterol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + albuterol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • albuterol inhaled
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + albuterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • alfentanil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    alfentanil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + alfentanil

    monitor respiratory rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, delayed recovery from anesthesia, other adverse effects (hepatic metabolism inhibited)

  • aliskiren
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + aliskiren

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • almotriptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    almotriptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + almotriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • alogliptin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    alogliptin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + alogliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + alogliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • amiloride
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + amiloride

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • aminocaproic acid
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    aminocaproic acid
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + aminocaproic acid

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + aminocaproic acid

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • aminophylline
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + aminophylline

    monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited; aminophylline converted to theophylline)

  • amiodarone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    amiodarone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + amiodarone

    monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • amlodipine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + amlodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amphetamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    amphetamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + amphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • angiotensin II
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    angiotensin II
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + angiotensin II

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + angiotensin II

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • anthrax immune globulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    anthrax immune globulin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + anthrax immune globulin

    monitor thrombosis s/sx; use lowest anthrax immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + anthrax immune globulin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest anthrax immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • anti-inhibitor coagulant complex
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    anti-inhibitor coagulant complex
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + anti-inhibitor coagulant complex

    monitor thrombosis s/sx, especially w/ anti-inhibitor coagulant complex dose >100 units/kg: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + anti-inhibitor coagulant complex

    monitor thrombosis s/sx, especially w/ concomitant estrogen use or anti-inhibitor coagulant complex dose >100 units/kg: combo may incr. risk of thromboembolism (additive effects)

  • antihemophilic factor (factor VIII)/von Willebrand factor complex
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    antihemophilic factor (factor VIII)/ von Willebrand factor complex
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + antihemophilic factor (factor VIII)/ von Willebrand factor complex

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + antihemophilic factor (factor VIII)/ von Willebrand factor complex

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • aprocitentan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    aprocitentan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + aprocitentan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • arformoterol inhaled
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    arformoterol inhaled
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + arformoterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • asciminib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    asciminib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + asciminib

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + asciminib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • asparaginase
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    asparaginase
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + asparaginase

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + asparaginase

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • atenolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + atenolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • atidarsagene autotemcel
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    atidarsagene autotemcel
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + atidarsagene autotemcel

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + atidarsagene autotemcel

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • atogepant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    atogepant
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + atogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atomoxetine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    atomoxetine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + atomoxetine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atropine ophthalmic
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    atropine ophthalmic
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + atropine ophthalmic

    monitor BP: combo may incr. risk of HTN (additive effects)

  • avacopan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    avacopan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + avacopan

    monitor thrombosis s/sx especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • avanafil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    avanafil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + avanafil

    monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • avatrombopag
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    avatrombopag
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + avatrombopag

    monitor platelets, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + avatrombopag

    monitor platelets, thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • axitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    axitinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + axitinib

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + axitinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • azilsartan medoxomil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + azilsartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • baricitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    baricitinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + baricitinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + baricitinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • belumosudil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    belumosudil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + belumosudil

    monitor thrombosis s/sx especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (UGT inhibited)

  • benazepril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + benazepril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • benzphetamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    benzphetamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + benzphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • berotralstat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    berotralstat
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + berotralstat

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • betamethasone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    betamethasone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + betamethasone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • betaxolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + betaxolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bevacizumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bevacizumab
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + bevacizumab

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + bevacizumab

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • bexagliflozin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bexagliflozin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + bexagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + bexagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • binimetinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    binimetinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + binimetinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + binimetinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • bismuth subsalicylate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bismuth subsalicylate
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

  • bisoprolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + bisoprolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • botulism immune globulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    botulism immune globulin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + botulism immune globulin

    monitor thrombosis s/sx; use lowest botulism immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + botulism immune globulin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest botulism immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • brolucizumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    brolucizumab
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + brolucizumab

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + brolucizumab

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • bromocriptine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bromocriptine
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + bromocriptine

    monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + bromocriptine

    monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • budesonide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    budesonide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + budesonide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bumetanide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + bumetanide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bupropion
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    bupropion
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + bupropion

    monitor BP: combo may incr. risk of HTN (additive effects)

  • C1 esterase inhibitor
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    C1 esterase inhibitor
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + C1 esterase inhibitor

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + C1 esterase inhibitor

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • cabozantinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cabozantinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + cabozantinib

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + cabozantinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • caffeine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    caffeine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + caffeine

    monitor BP; avoid excessive caffeine intake: combo may incr. caffeine levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • caffeine citrate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + caffeine citrate

    monitor caffeine levels, BP: combo may incr. caffeine levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • calaspargase
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    calaspargase
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + calaspargase

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + calaspargase

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • canagliflozin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    canagliflozin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + canagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + canagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • candesartan cilexetil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + candesartan cilexetil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • capivasertib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    capivasertib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + capivasertib

    monitor glucose, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of severe hyperglycemia, thromboembolism, other adverse effects (hepatic metabolism inhibited, UGT inhibited)

  • captopril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + captopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • carvedilol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    carvedilol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + carvedilol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • celecoxib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    celecoxib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + celecoxib

    monitor BP, thrombosis s/sx; use lowest effective celecoxib dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + celecoxib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective celecoxib dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • ceritinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ceritinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ceritinib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • chloramphenicol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    chloramphenicol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + chloramphenicol

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • chlorothiazide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + chlorothiazide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • chlorthalidone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + chlorthalidone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cholestyramine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cholestyramine
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + cholestyramine

    give oral contraceptive at least 1h before or 4-6h after each cholestyramine dose: combo may decr. ethinyl estradiol levels, contraceptive efficacy (absorption decreased/delayed)

    norgestrel (contraceptive) + cholestyramine

    give oral contraceptive at least 1h before or 4-6h after each cholestyramine dose: combo may decr. norgestrel levels, contraceptive efficacy (absorption decreased/delayed)

  • chorionic gonadotropin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    chorionic gonadotropin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + chorionic gonadotropin

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + chorionic gonadotropin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • ciprofloxacin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ciprofloxacin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ciprofloxacin

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • citalopram
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    citalopram
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + citalopram

    adjust max citalopram dose to 20 mg/day: combo may incr. citalopram levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • clarithromycin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    clarithromycin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + clarithromycin

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • clevidipine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    clevidipine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + clevidipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clofazimine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    clofazimine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + clofazimine

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • clonidine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + clonidine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clozapine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    clozapine
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + clozapine

    monitor ECG, BP, HR, thrombosis s/sx; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, thromboembolism, other adverse effects (hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + clozapine

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor IX
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    coagulation factor IX
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + coagulation factor IX

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + coagulation factor IX

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor VIIa
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    coagulation factor VIIa
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + coagulation factor VIIa

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + coagulation factor VIIa

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor XIII A-subunit
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    coagulation factor XIII A-subunit
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + coagulation factor XIII A-subunit

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + coagulation factor XIII A-subunit

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • cobicistat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cobicistat
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + cobicistat

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • cocaine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cocaine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + cocaine

    monitor BP, HR: combo may incr. cocaine levels, risk of HTN, tachycardia, other adverse effects (plasma metabolism possibly inhibited, additive effects)

  • colesevelam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    colesevelam
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + colesevelam

    give oral contraceptive at least 4h before each colesevelam dose; monitor glucose in type 2 diabetes mellitus pts: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption decreased/delayed; antagonistic effects)

    norgestrel (contraceptive) + colesevelam

    give oral contraceptive at least 4h before each colesevelam dose; monitor glucose in type 2 diabetes mellitus pts: combo may decr. norgestrel levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption decreased/delayed; antagonistic effects)

  • colestipol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    colestipol
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + colestipol

    give oral contraceptive at least 1h before or 4h after each colestipol dose: combo may decr. ethinyl estradiol levels, contraceptive efficacy (absorption decreased/delayed)

    norgestrel (contraceptive) + colestipol

    give oral contraceptive at least 1h before or 4h after each colestipol dose: combo may decr. norgestrel levels, contraceptive efficacy (absorption decreased/delayed)

  • concizumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    concizumab
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + concizumab

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + concizumab

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • conivaptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    conivaptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + conivaptan

    monitor thrombosis s/sx during and x7 days after conivaptan tx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of thromboembolism, overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)

  • copanlisib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    copanlisib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + copanlisib

    monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

  • corticotropin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    corticotropin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + corticotropin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • cortisone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cortisone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + cortisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • cosyntropin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cosyntropin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + cosyntropin

    hold ethinyl estradiol 4-6wk prior to test: combo may interfere with test results (ethinyl estradiol may alter plasma cortisol levels)

  • crizotinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    crizotinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + crizotinib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • cyclosporine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cyclosporine
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + cyclosporine

    monitor cyclosporine levels, renal fxn, BP, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of serious infection, nephrotoxicity, HTN, thromboembolism, other adverse effects (hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + cyclosporine

    monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects (hepatic metabolism possibly inhibited)

  • cytomegalovirus immune globulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cytomegalovirus immune globulin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + cytomegalovirus immune globulin

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + cytomegalovirus immune globulin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • danazol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    danazol
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + danazol

    monitor BP, thrombosis s/sx: combo may incr. ethinyl estradiol levels, risk of HTN, thromboembolism, other adverse effects (hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + danazol

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • dapagliflozin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dapagliflozin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dapagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + dapagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • darbepoetin alfa
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    darbepoetin alfa
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + darbepoetin alfa

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + darbepoetin alfa

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • deflazacort
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    deflazacort
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + deflazacort

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + deflazacort

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • desipramine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + desipramine

    monitor ECG; consider monitoring desipramine levels: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • desmopressin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    desmopressin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + desmopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • desvenlafaxine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    desvenlafaxine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + desvenlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • deuruxolitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    deuruxolitinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + deuruxolitinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + deuruxolitinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • dexmethylphenidate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dexmethylphenidate
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dexmethylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dextroamphetamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dextroamphetamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dextroamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diazepam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    diazepam
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + diazepam

    monitor respiratory rate: combo may incr. diazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • diclofenac
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    diclofenac
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + diclofenac

    monitor BP, thrombosis s/sx; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + diclofenac

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • diclofenac topical
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    diclofenac topical
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + diclofenac topical

    monitor BP, thrombosis s/sx; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + diclofenac topical

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • diethylpropion
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    diethylpropion
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + diethylpropion

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diflunisal
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    diflunisal
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + diflunisal

    monitor BP, thrombosis s/sx; use lowest effective diflunisal dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + diflunisal

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective diflunisal dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • dihydroergotamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dihydroergotamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dihydroergotamine

    monitor BP: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • diltiazem
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + diltiazem

    monitor BP, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • disopyramide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    disopyramide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + disopyramide

    monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • dobutamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dobutamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dobutamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • docetaxel
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    docetaxel
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + docetaxel

    monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • dofetilide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dofetilide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dofetilide

    monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • domperidone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    domperidone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + domperidone

    monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • dopamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dopamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dopamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • doxapram
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    doxapram
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + doxapram

    monitor BP: combo may incr. risk of HTN (additive effects)

  • doxazosin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + doxazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dronabinol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dronabinol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dronabinol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dronedarone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dronedarone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + dronedarone

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • droxidopa
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    droxidopa
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + droxidopa

    monitor BP: combo may incr. risk of supine HTN (additive effects)

  • duvelisib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    duvelisib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + duvelisib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • eletriptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    eletriptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + eletriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eltrombopag
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    eltrombopag
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + eltrombopag

    monitor platelets, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + eltrombopag

    monitor platelets, thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • empagliflozin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    empagliflozin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + empagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + empagliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • enalapril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + enalapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • enalaprilat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + enalaprilat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • entrectinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    entrectinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + entrectinib

    monitor ECG, CBC: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • ephedra
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ephedra
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ephedra

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ephedrine injection
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ephedrine injection
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ephedrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ephedrine oral
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ephedrine oral
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ephedrine oral

    monitor BP: combo may incr. risk of HTN (additive effects)

  • epinephrine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    epinephrine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + epinephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • epirubicin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    epirubicin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + epirubicin

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + epirubicin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • eplerenone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + eplerenone

    monitor potassium, BP: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • epoetin alfa
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    epoetin alfa
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + epoetin alfa

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + epoetin alfa

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • eptinezumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    eptinezumab
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + eptinezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • erenumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    erenumab
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + erenumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ergotamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ergotamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ergotamine

    monitor BP: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ertugliflozin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ertugliflozin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ertugliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + ertugliflozin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • erythromycin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + erythromycin

    monitor ECG, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • esketamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    esketamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + esketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • esmolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + esmolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ethacrynic acid
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ethacrynic acid

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ethanol (alcoholic beverage)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

  • etodolac
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    etodolac
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + etodolac

    monitor BP, thrombosis s/sx; use lowest effective etodolac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + etodolac

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective etodolac dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • etrasimod
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    etrasimod
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + etrasimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • everolimus
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    everolimus
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + everolimus

    monitor thrombosis s/sx, especially if immunosuppressant use; TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, thromboembolism, other adverse effects (hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + everolimus

    monitor thrombosis s/sx, especially w/ concomitant estrogen or immunosuppressant use: combo may incr. risk of thromboembolism (additive effects)

  • exenatide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    exenatide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + exenatide

    monitor glucose; give oral contraceptive at least 1h before twice daily exenatide; caution w/ weekly exenatide: combo may decr. peak ethinyl estradiol levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

    norgestrel (contraceptive) + exenatide

    monitor glucose; give oral contraceptive at least 1h before twice daily exenatide; caution w/ weekly exenatide: combo may decr. peak norgestrel levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects)

  • factor XIII concentrate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    factor XIII concentrate
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + factor XIII concentrate

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + factor XIII concentrate

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • faricimab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    faricimab
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + faricimab

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + faricimab

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • fedratinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fedratinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fedratinib

    monitor CBC, LFTs, thrombosis s/sx: combo may incr. levels of both drugs, risk of myelosuppression, hepatotoxicity, thromboembolism, other adverse effects (hepatic metabolism inhibited, additive effects)

    norgestrel (contraceptive) + fedratinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • felodipine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + felodipine

    monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • fenfluramine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fenfluramine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fenfluramine

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • fenofibrate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fenofibrate
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fenofibrate

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + fenofibrate

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • fenofibric acid
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fenofibric acid
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fenofibric acid

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + fenofibric acid

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • fenoldopam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fenoldopam
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fenoldopam

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenoprofen
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fenoprofen
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fenoprofen

    monitor BP, thrombosis s/sx; use lowest effective fenoprofen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + fenoprofen

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective fenoprofen dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • fentanyl
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fentanyl
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fentanyl

    monitor respiratory rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ferric maltol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ferric maltol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ferric maltol

    separate admin. w/ oral ethinyl estradiol by at least 4h: combo may decr. ethinyl estradiol levels, contraceptive efficacy (absorption decreased via chelation)

  • fibrinogen (human)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fibrinogen (human)
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fibrinogen (human)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + fibrinogen (human)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • finerenone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    finerenone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + finerenone

    monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • fingolimod
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fingolimod
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fingolimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • flecainide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    flecainide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + flecainide

    monitor flecainide levels, ECG: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • flibanserin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    flibanserin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + flibanserin

    monitor BP: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

  • fluconazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fluconazole
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fluconazole

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • fludrocortisone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fludrocortisone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fludrocortisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fluorouracil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fluorouracil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fluorouracil

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • flurbiprofen
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    flurbiprofen
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + flurbiprofen

    monitor BP, thrombosis s/sx; use lowest effective flurbiprofen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + flurbiprofen

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective flurbiprofen dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • follitropin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    follitropin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + follitropin

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + follitropin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • formoterol inhaled
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    formoterol inhaled
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + formoterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fosinopril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fosinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fostamatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fostamatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fostemsavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fostemsavir
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fostemsavir

    do not exceed 30 mcg oral ethinyl estradiol/day; monitor thrombosis s/sx: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (mechanism unknown)

  • fremanezumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fremanezumab
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fremanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • frovatriptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    frovatriptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + frovatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fruquintinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fruquintinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + fruquintinib

    monitor BP, thrombosis s/sx: combo may incr. risk of thromboembolism, HTN, including hypertensive crisis (additive effects)

    norgestrel (contraceptive) + fruquintinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • galcanezumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    galcanezumab
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + galcanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • gemfibrozil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    gemfibrozil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + gemfibrozil

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (UGT inhibited)

  • gepirone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    gepirone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + gepirone

    monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • glimepiride
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    glimepiride
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + glimepiride

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + glimepiride

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • glipizide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    glipizide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + glipizide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + glipizide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • glyburide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    glyburide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + glyburide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + glyburide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • grapefruit
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    grapefruit
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + grapefruit

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (GI metabolism inhibited)

  • guanfacine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + guanfacine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hepatitis B immune globulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    hepatitis B immune globulin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + hepatitis B immune globulin

    monitor thrombosis s/sx; use lowest hepatitis B immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + hepatitis B immune globulin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest hepatitis B immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • hoodia
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    hoodia
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + hoodia

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydralazine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + hydralazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrochlorothiazide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + hydrochlorothiazide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrocortisone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + hydrocortisone

    monitor BP; consider hydrocortisone dose adjustment: combo may decr. hydrocortisone levels, efficacy; may incr. risk of HTN (altered cortisol-binding globulin activity; additive effects)

  • hydroxocobalamin IV
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + hydroxocobalamin IV

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibrutinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ibrutinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ibrutinib

    monitor BP; consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of HTN, serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ibuprofen
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ibuprofen
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ibuprofen

    monitor BP, thrombosis s/sx; use lowest effective ibuprofen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + ibuprofen

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective ibuprofen dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • idelalisib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    idelalisib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + idelalisib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • imatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    imatinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + imatinib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • immune globulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    immune globulin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + immune globulin

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + immune globulin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • indapamide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + indapamide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • indomethacin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    indomethacin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + indomethacin

    monitor BP, thrombosis s/sx; use lowest effective indomethacin dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + indomethacin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective indomethacin dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • insulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    insulin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + insulin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + insulin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • iodixanol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    iodixanol
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + iodixanol

    monitor thrombosis signs/symptoms: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + iodixanol

    monitor thrombosis signs/symptoms, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • iohexol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    iohexol
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + iohexol

    if IV iohexol use, monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + iohexol

    if IV iohexol use, monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • iomeprol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    iomeprol
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + iomeprol

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + iomeprol

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • iopamidol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    iopamidol
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + iopamidol

    if IV iopamidol use, monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + iopamidol

    if IV iopamidol use, monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • iopromide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    iopromide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + iopromide

    monitor thrombosis signs/symptoms: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + iopromide

    monitor thrombosis signs/symptoms, especially with concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • iothalamate meglumine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    iothalamate meglumine
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + iothalamate meglumine

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + iothalamate meglumine

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • ioversol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ioversol
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ioversol

    monitor thrombosis signs/symptoms: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + ioversol

    monitor thrombosis signs/symptoms, especially with concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • irbesartan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + irbesartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • isradipine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + isradipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • itraconazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    itraconazole
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + itraconazole

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • ivabradine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ivabradine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ivabradine

    monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ixabepilone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ixabepilone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ixabepilone

    monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)

  • ketamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ketamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketoconazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ketoconazole
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ketoconazole

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited, UGT inhibited)

  • ketoprofen
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ketoprofen
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ketoprofen

    monitor BP, thrombosis s/sx; use lowest effective ketoprofen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + ketoprofen

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective ketoprofen dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • ketorolac
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ketorolac
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ketorolac

    monitor BP, thrombosis s/sx; use lowest effective ketorolac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + ketorolac

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective ketorolac dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • labetalol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    labetalol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + labetalol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lamotrigine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lamotrigine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lamotrigine

    consider gradual incr. of lamotrigine maint. dose up to 2-fold, initial dose escalation unchanged; no change if also on carbamazepine, phenytoin, phenobarbital, primidone, rifampin, or ritonavir: combo may decr. lamotrigine levels, efficacy; transient incr. of lamotrigine levels, adverse effects may occur during inert tab phase (UGT induced)

  • lanreotide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lanreotide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lazertinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lazertinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lazertinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + lazertinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • lefamulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lefamulin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lefamulin

    ORAL LEFAMULIN: monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day; IV lefamulin use OK: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • leflunomide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + leflunomide

    monitor BP, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of HTN, thromboembolism, other adverse effects (mechanism unknown, additive effects)

  • lemborexant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lemborexant
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lemborexant

    adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • lenacapavir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lenacapavir
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lenacapavir

    monitor thrombosis s/sx during and x9mo after lenacapavir tx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • lenalidomide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lenalidomide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lenalidomide

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + lenalidomide

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • lenvatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lenvatinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lenvatinib

    monitor BP, thrombosis s/sx: combo may incr. ethinyl estradiol levels, risk of HTN, thromboembolism, other adverse effects (UGT possibly inhibited, additive effects)

    norgestrel (contraceptive) + lenvatinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • letermovir
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    letermovir
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + letermovir

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • levalbuterol inhaled
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + levalbuterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • levoketoconazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    levoketoconazole
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + levoketoconazole

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day; consider monitoring ECG: combo may incr. levels of both drugs, risk of thromboembolism, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • levomilnacipran
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + levomilnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

  • levothyroxine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    levothyroxine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + levothyroxine

    monitor thyroid fxn: combo may decr. thyroid hormone efficacy (thyroid hormone uptake altered)

  • licorice
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    licorice
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + licorice

    monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects)

  • lidocaine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lidocaine

    monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

  • linagliptin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    linagliptin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + linagliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + linagliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • liothyronine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    liothyronine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + liothyronine

    monitor thyroid fxn: combo may decr. thyroid hormone efficacy (thyroid hormone uptake altered)

  • lisdexamfetamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lisdexamfetamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lisdexamfetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lisinopril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lisinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lomitapide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lomitapide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lomitapide

    ADULT PATIENTS: if patient on stable ethinyl estradiol dose and starting lomitapide, adjust max lomitapide dose to 40 mg/day; if patient on stable lomitapide dose and starting ethinyl estradiol, decr. lomitapide dose by one-third and adjust max lomitapide dose to 40 mg/day; PEDIATRIC PATIENTS: if patient on stable ethinyl estradiol dose and starting lomitapide, adjust max lomitapide dose to 15 mg/day if 2-10 yo or 30 mg/day if 11-17 yo; if patient on stable lomitapide dose and starting ethinyl estradiol, decr. lomitapide dose by one-third and adjust max lomitapide dose to 15 mg/day if 2-10 yo or 30 mg/day if 11-17 yo: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lonafarnib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lonafarnib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lonafarnib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day; consider monitoring HR, ECG, electrolytes: combo may incr. levels of both drugs, risk of thromboembolism, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lorazepam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lorazepam
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lorazepam

    consider lorazepam dose adjustment: combo may decr. lorazepam levels, efficacy (mechanism unknown)

  • losartan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + losartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lovastatin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lovastatin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lovastatin

    monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • lumateperone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lumateperone

    monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lurasidone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lurasidone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lurasidone

    monitor ECG: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lurbinectedin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lurbinectedin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lurbinectedin

    monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • luspatercept
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    luspatercept
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + luspatercept

    monitor BP; if beta thalassemia use, monitor thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + luspatercept

    if beta thalassemia use, monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • lusutrombopag
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    lusutrombopag
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + lusutrombopag

    monitor platelets, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + lusutrombopag

    monitor platelets, thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • magnesium salicylate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + magnesium salicylate

    monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

  • meclofenamate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    meclofenamate
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + meclofenamate

    monitor BP, thrombosis s/sx; use lowest effective meclofenamate dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + meclofenamate

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective meclofenamate dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • mefenamic acid
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    mefenamic acid
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + mefenamic acid

    monitor BP, thrombosis s/sx; use lowest effective mefenamic acid dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + mefenamic acid

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective mefenamic acid dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • meloxicam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    meloxicam
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + meloxicam

    monitor BP, thrombosis s/sx; use lowest effective meloxicam dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + meloxicam

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective meloxicam dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • menotropins
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    menotropins
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + menotropins

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + menotropins

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • metformin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    metformin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + metformin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + metformin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • methamphetamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    methamphetamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + methamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    methoxy polyethylene glycol-epoetin beta
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + methoxy polyethylene glycol-epoetin beta

    monitor BP, thrombosis s/sx: combo may incr. HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + methoxy polyethylene glycol-epoetin beta

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • methyldopa
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    methyldopa
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + methyldopa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylergonovine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    methylergonovine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + methylergonovine

    monitor BP: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • methylphenidate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    methylphenidate
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + methylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methylprednisolone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    methylprednisolone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + methylprednisolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methyltestosterone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    methyltestosterone
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + methyltestosterone

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + methyltestosterone

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • metoclopramide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    metoclopramide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + metoclopramide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metolazone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + metolazone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • metoprolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + metoprolol

    monitor BP: combo may incr. metoprolol levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • metyrapone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    metyrapone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + metyrapone

    D/C ethinyl estradiol 5 half-lives before metyrapone test: combo may decr. metyrapone levels, efficacy; test results may be inaccurate (UGT possibly induced; antagonistic effects)

  • midazolam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    midazolam
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + midazolam

    monitor respiratory rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • miglitol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    miglitol
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + miglitol

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + miglitol

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • milnacipran
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    milnacipran
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + milnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

  • minoxidil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    minoxidil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + minoxidil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mirabegron
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    mirabegron
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + mirabegron

    monitor BP: combo may incr. risk of HTN (additive effects)

  • moexipril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + moexipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • momelotinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    momelotinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + momelotinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + momelotinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • nabumetone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nabumetone
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nabumetone

    monitor BP, thrombosis s/sx; use lowest effective nabumetone dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + nabumetone

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective nabumetone dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • nadolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nadolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nadolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • naproxen
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    naproxen
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + naproxen

    monitor BP, thrombosis s/sx; use lowest effective naproxen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + naproxen

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective naproxen dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • naratriptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    naratriptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + naratriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nateglinide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nateglinide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nateglinide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + nateglinide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • naxitamab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + naxitamab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nebivolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nebivolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nebivolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • necitumumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    necitumumab
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + necitumumab

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + necitumumab

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • nefazodone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nefazodone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nefazodone

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • nicardipine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nicardipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nifedipine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nifedipine

    monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • nilotinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nilotinib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • nimodipine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nimodipine

    monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects; may decr. nimodipine efficacy (hepatic metabolism inhibited; antagonistic effects)

  • nintedanib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nintedanib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nintedanib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + nintedanib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • niraparib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + niraparib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nisoldipine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nisoldipine

    monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • norepinephrine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    norepinephrine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + norepinephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nortriptyline
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + nortriptyline

    monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

  • obinutuzumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    obinutuzumab
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + obinutuzumab

    monitor BP, thrombosis s/sx: combo may incr. risk of thromboembolism, HTN, including hypertensive crisis (additive effects)

    norgestrel (contraceptive) + obinutuzumab

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • olaparib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    olaparib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + olaparib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + olaparib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • oliceridine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + oliceridine

    monitor respiratory rate, ECG: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • olmesartan medoxomil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + olmesartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • olodaterol inhaled
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    olodaterol inhaled
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + olodaterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • osilodrostat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + osilodrostat

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxaprozin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    oxaprozin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + oxaprozin

    monitor BP, thrombosis s/sx; use lowest effective oxaprozin dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + oxaprozin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective oxaprozin dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • oxymetazoline nasal
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    oxymetazoline nasal
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + oxymetazoline nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxytocin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    oxytocin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + oxytocin

    monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

  • ozanimod
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ozanimod
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ozanimod

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • pazopanib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pazopanib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + pazopanib

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + pazopanib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • pegaspargase
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pegaspargase
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + pegaspargase

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + pegaspargase

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • pemigatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pemigatinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + pemigatinib

    monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • perindopril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + perindopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phendimetrazine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phendimetrazine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phendimetrazine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenoxybenzamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phenoxybenzamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phenoxybenzamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phentermine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phentermine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phentermine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phentolamine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phentolamine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phentolamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phenylephrine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phenylephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine injection
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phenylephrine injection
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phenylephrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine nasal
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phenylephrine nasal
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phenylephrine nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine ophthalmic
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phenylephrine ophthalmic
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phenylephrine ophthalmic

    monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN (additive effects)

  • phenylephrine rectal
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    phenylephrine rectal
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + phenylephrine rectal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pindolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pindolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + pindolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • piroxicam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    piroxicam
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + piroxicam

    monitor BP, thrombosis s/sx; use lowest effective piroxicam dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + piroxicam

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective piroxicam dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • pomalidomide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pomalidomide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + pomalidomide

    monitor CBC, thrombosis s/sx: combo may incr. pomalidomide levels, risk of serious infection, myelosuppression, other adverse effects; may incr. risk of thromboembolism (hepatic metabolism inhibited; additive effects)

    norgestrel (contraceptive) + pomalidomide

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • ponatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ponatinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ponatinib

    monitor thrombosis s/sx, BP: combo may incr. risk of thromboembolism, HTN (additive effects)

    norgestrel (contraceptive) + ponatinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • ponesimod
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ponesimod
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ponesimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • porfimer
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    porfimer
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + porfimer

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + porfimer

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • pramlintide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pramlintide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + pramlintide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + pramlintide

    give oral contraceptive at least 1h before or 2h after pramlintide; monitor glucose: combo may decr. peak norgestrel levels, contraceptive efficacy; may decr. antidiabetic agent efficacy (absorption delayed; antagonistic effects)

  • prazosin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + prazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • prednisolone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    prednisolone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + prednisolone

    monitor BP: combo may incr. prednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, HTN, other adverse effects (hepatic metabolism possibly inhibited, additive effects)

  • probenecid
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    probenecid
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + probenecid

    monitor thrombosis s/sx especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (UGT inhibited)

  • propranolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    propranolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + propranolol

    monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • prothrombin complex concentrate (human)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    prothrombin complex concentrate (human)
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + prothrombin complex concentrate (human)

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + prothrombin complex concentrate (human)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • pseudoephedrine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    pseudoephedrine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + pseudoephedrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • quetiapine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    quetiapine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + quetiapine

    monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

  • quinapril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + quinapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • quinidine (antiarrhythmic)
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + quinidine (antiarrhythmic)

    monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ramipril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ramipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramucirumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ramucirumab
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ramucirumab

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + ramucirumab

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • ranibizumab
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ranibizumab
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ranibizumab

    monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + ranibizumab

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

  • rasagiline
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + rasagiline

    adjust max rasagiline dose to 0.5 mg/day: combo may incr. rasagiline levels, risk of adverse effects (hepatic metabolism inhibited)

  • red yeast rice
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    red yeast rice
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + red yeast rice

    monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

  • regorafenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    regorafenib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + regorafenib

    monitor BP, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of HTN, thromboembolism, other adverse effects (UGT inhibited, additive effects)

  • repaglinide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    repaglinide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + repaglinide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + repaglinide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • Rho(D) immune globulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    Rho(D) immune globulin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + Rho(D) immune globulin

    monitor thrombosis s/sx; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + Rho(D) immune globulin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • ribociclib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ribociclib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ribociclib

    monitor ECG, electrolytes, CBC, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • rilzabrutinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rilzabrutinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + rilzabrutinib

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • rimegepant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rimegepant
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + rimegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ripretinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ripretinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ripretinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ritlecitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ritlecitinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ritlecitinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + ritlecitinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • rizatriptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rizatriptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + rizatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • romiplostim
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    romiplostim
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + romiplostim

    monitor platelets, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + romiplostim

    monitor platelets, thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • ropinirole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ropinirole

    monitor BP; consider decr. ropinirole dose: combo may incr. ropinirole levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • rosiglitazone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rosiglitazone
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + rosiglitazone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + rosiglitazone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • rotigotine transdermal
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + rotigotine transdermal

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • ruxolitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ruxolitinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ruxolitinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + ruxolitinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • ruxolitinib topical
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ruxolitinib topical
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ruxolitinib topical

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + ruxolitinib topical

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • salmeterol inhaled
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    salmeterol inhaled
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + salmeterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • salsalate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    salsalate
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + salsalate

    monitor thrombosis s/sx, BP w/ high-dose salsalate: combo may incr. risk of thromboembolism, HTN (additive effects)

    norgestrel (contraceptive) + salsalate

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • saxagliptin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    saxagliptin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + saxagliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + saxagliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • selpercatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + selpercatinib

    monitor ECG, electrolytes, BP: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • semaglutide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    semaglutide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + semaglutide

    monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + semaglutide

    monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • sevelamer
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sevelamer
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sevelamer

    consider giving oral contraceptive at least 1h before or 3h after each sevelamer dose: combo may decr. ethinyl estradiol levels, contraceptive efficacy (absorption decreased/delayed)

    norgestrel (contraceptive) + sevelamer

    consider giving oral contraceptive at least 1h before or 3h after each sevelamer dose: combo may decr. norgestrel levels, contraceptive efficacy (absorption decreased/delayed)

  • siponimod
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    siponimod
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + siponimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sipuleucel-T
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sipuleucel-T
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sipuleucel-T

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + sipuleucel-T

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • sirolimus
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sirolimus

    monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited)

  • sirolimus albumin-bound
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sirolimus albumin-bound
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sirolimus albumin-bound

    decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • sitagliptin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sitagliptin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sitagliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

    norgestrel (contraceptive) + sitagliptin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • sodium tetradecyl sulfate
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sodium tetradecyl sulfate
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sodium tetradecyl sulfate

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + sodium tetradecyl sulfate

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • solriamfetol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    solriamfetol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + solriamfetol

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • somapacitan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    somapacitan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + somapacitan

    incr. somapacitan start dose to 2 mg qwk: combo may decr. somapacitan efficacy (antagonistic effects, oral estrogens may reduce serum IGF-1 response)

  • somatrogon
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    somatrogon
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + somatrogon

    consider somatrogon dose adjustment: combo may decr. somatrogon efficacy (antagonistic effects, oral estrogens may reduce serum IGF-1 response)

  • somatropin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    somatropin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + somatropin

    consider incr. somatropin dose: combo may decr. somatropin efficacy (antagonistic effects, oral estrogens may reduce serum IGF-1 response)

  • sorafenib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sorafenib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sorafenib

    monitor BP, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of HTN, thromboembolism, other adverse effects (UGT inhibited, additive effects)

  • sotatercept
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sotatercept
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sotatercept

    monitor Hgb, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + sotatercept

    monitor Hgb, thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • spironolactone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + spironolactone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • sufentanil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sufentanil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sufentanil

    monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • sulindac
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sulindac
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sulindac

    monitor BP, thrombosis s/sx; use lowest effective sulindac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + sulindac

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective sulindac dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • sumatriptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sumatriptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sumatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sunitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + sunitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tacrolimus
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tacrolimus

    monitor tacrolimus levels, ECG, BP, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, HTN, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • tadalafil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tadalafil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tadalafil

    monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • tagraxofusp
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tagraxofusp

    monitor BP: combo may incr. risk of HTN (additive effects)

  • taletrectinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    taletrectinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + taletrectinib

    monitor ECG: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • telmisartan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + telmisartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • temsirolimus
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + temsirolimus

    monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • terazosin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + terazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terbutaline
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + terbutaline

    monitor BP: combo may incr. risk of HTN (additive effects)

  • teriflunomide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + teriflunomide

    monitor BP, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of HTN, thromboembolism, other adverse effects (mechanism unknown, additive effects)

  • testosterone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    testosterone
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + testosterone

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + testosterone

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • thalidomide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    thalidomide
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + thalidomide

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + thalidomide

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • theophylline
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    theophylline
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + theophylline

    monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited)

  • thyroid
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    thyroid
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + thyroid

    monitor thyroid fxn: combo may decr. thyroid hormone efficacy (thyroid hormone uptake altered)

  • timolol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    timolol
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + timolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tivozanib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tivozanib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tivozanib

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN (including hypertensive crisis), thromboembolism (additive effects)

    norgestrel (contraceptive) + tivozanib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • tofacitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tofacitinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tofacitinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + tofacitinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • tolmetin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tolmetin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tolmetin

    monitor BP, thrombosis s/sx; use lowest effective tolmetin dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + tolmetin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective tolmetin dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)

  • tolvaptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tolvaptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tolvaptan

    consider decr. tolvaptan dose: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • torsemide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + torsemide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • trametinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    trametinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + trametinib

    monitor BP, thrombosis s/sx, especially in combo w/ dabrafenib: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + trametinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use or in combo w/ dabrafenib: combo may incr. risk of thromboembolism (additive effects)

  • trandolapril
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + trandolapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tretinoin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tretinoin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tretinoin

    monitor thrombosis s/sx, especially during 1st month of tretinoin use: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + tretinoin

    monitor thrombosis s/sx, especially during 1st month of tretinoin use and/or concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • triamcinolone
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    triamcinolone
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + triamcinolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • triamterene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + triamterene

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triazolam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    triazolam
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + triazolam

    monitor respiratory rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • triclabendazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    triclabendazole
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + triclabendazole

    monitor ECG: combo may incr. triclabendazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • tucatinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    tucatinib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + tucatinib

    monitor thrombosis s/sx especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • ubrogepant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ubrogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • upadacitinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    upadacitinib
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + upadacitinib

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + upadacitinib

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • vadadustat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vadadustat
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + vadadustat

    monitor BP, Hgb, thrombosis s/sx; use lowest effective vadadustat dose: combo may incr. risk of HTN (including hypertensive crisis), thromboembolism (additive effects)

    norgestrel (contraceptive) + vadadustat

    monitor Hgb, thrombosis s/sx, especially w/ concomitant estrogen use; use lowest effective vadadustat dose: combo may incr. risk of thromboembolism (additive effects)

  • valoctocogene roxaparvovec
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    valoctocogene roxaparvovec
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + valoctocogene roxaparvovec

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + valoctocogene roxaparvovec

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • valsartan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + valsartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vandetanib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vandetanib
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + vandetanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vardenafil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vardenafil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + vardenafil

    monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • varicella zoster immune globulin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    varicella zoster immune globulin
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + varicella zoster immune globulin

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + varicella zoster immune globulin

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • vasopressin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vasopressin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + vasopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • venetoclax
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    venetoclax
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + venetoclax

    monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

  • venlafaxine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + venlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • verapamil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + verapamil

    monitor BP, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, thromboembolism, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

  • vilanterol inhaled
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vilanterol inhaled
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + vilanterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • viloxazine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    viloxazine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + viloxazine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • vincristine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vincristine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + vincristine

    monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • vinorelbine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vinorelbine
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + vinorelbine

    monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • voclosporin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + voclosporin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • von Willebrand factor
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    von Willebrand factor
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + von Willebrand factor

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + von Willebrand factor

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • voriconazole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    voriconazole
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + voriconazole

    monitor ECG, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • vorinostat
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    vorinostat
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + vorinostat

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + vorinostat

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • warfarin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    warfarin
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + warfarin

    monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • yohimbe
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + yohimbe

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zavegepant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    zavegepant
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + zavegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ziv-aflibercept
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ziv-aflibercept
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + ziv-aflibercept

    monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

    norgestrel (contraceptive) + ziv-aflibercept

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

  • zolmitriptan
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    zolmitriptan
    1 interaction

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + zolmitriptan

    monitor BP: combo may incr. zolmitriptan levels, risk of HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

  • zopapogene imadenovec
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    zopapogene imadenovec
    2 interactions

    Monitor/Modify Tx

    ethinyl estradiol (contraceptive) + zopapogene imadenovec

    monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

    norgestrel (contraceptive) + zopapogene imadenovec

    monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

Caution Advised

  • cariprazine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cariprazine
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + cariprazine

    caution advised: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • carisoprodol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    carisoprodol
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + carisoprodol

    caution advised: combo may incr. carisoprodol levels, decr. active metabolite meprobamate levels, alter risk of adverse effects and efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • clopidogrel
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    clopidogrel
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + clopidogrel

    caution advised: combo may decr. clopidogrel active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion of clopidogrel to active metabolite)

  • cobimetinib
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cobimetinib
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + cobimetinib

    caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • cyclophosphamide
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    cyclophosphamide
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + cyclophosphamide

    caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy (hepatic metabolism possibly inhibited, decr. conversion to active metabolite)

  • dantrolene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    dantrolene
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + dantrolene

    caution advised, especially in pts >35 yo: combo may incr. risk of hepatotoxicity (additive effects)

  • daridorexant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    daridorexant
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + daridorexant

    caution advised: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • duloxetine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    duloxetine
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + duloxetine

    caution advised: combo may incr. duloxetine levels, risk of adverse effects (hepatic metabolism inhibited)

  • elacestrant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    elacestrant
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + elacestrant

    caution advised: combo may decr. elacestrant efficacy (antagonistic effects)

  • elinzanetant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    elinzanetant
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + elinzanetant

    caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • fulvestrant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    fulvestrant
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + fulvestrant

    caution advised: combo may decr. fulvestrant efficacy (antagonistic effects)

  • imlunestrant
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    imlunestrant
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + imlunestrant

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • melatonin
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    melatonin
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + melatonin

    caution advised: combo may incr. melatonin levels, risk of adverse effects (hepatic metabolism inhibited)

  • palovarotene
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    palovarotene
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + palovarotene

    caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

  • perphenazine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    perphenazine
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + perphenazine

    caution advised: combo may incr. perphenazine levels, risk of adverse effects (hepatic metabolism inhibited)

  • proguanil
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    proguanil
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + proguanil

    caution advised: combo may incr. proguanil levels, risk of adverse effects; may decr. proguanil active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • ramelteon
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ramelteon
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + ramelteon

    caution advised: combo may incr. ramelteon levels, risk of adverse effects (hepatic metabolism inhibited)

  • riluzole
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    riluzole
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + riluzole

    caution advised: combo may incr. riluzole levels, risk of adverse effects (hepatic metabolism inhibited)

  • roflumilast
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    roflumilast
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + roflumilast

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • roflumilast topical
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    roflumilast topical
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + roflumilast topical

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • selegiline
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    selegiline
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + selegiline

    caution advised: combo may incr. selegiline levels, risk of adverse effects (hepatic metabolism inhibited)

  • sirolimus topical
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    sirolimus topical
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + sirolimus topical

    caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

  • temazepam
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    temazepam
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + temazepam

    caution advised: combo may decr. temazepam levels, efficacy (UGT possibly induced)

  • trifluoperazine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    trifluoperazine
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + trifluoperazine

    caution advised: combo may decr. trifluoperazine levels, efficacy (UGT induced)

  • trimipramine
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    trimipramine
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + trimipramine

    caution advised: combo may incr. trimipramine levels, risk of adverse effects (hepatic metabolism inhibited)

  • ursodiol
  • Turqoz (norgestrel/ ethinyl estradiol)
    +
    ursodiol
    1 interaction

    Caution Advised

    ethinyl estradiol (contraceptive) + ursodiol

    caution advised: combo may decr. ursodiol efficacy (antagonistic effects, estrogens promote gallstone formation)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@34e339f0
  • thrombosis
  • thromboembolism
  • MI
  • stroke
  • cerebral hemorrhage
  • HTN
  • hepatic adenoma
  • cholestasis
  • gallbladder disease
  • pancreatitis
  • depression
  • anaphylaxis
  • anaphylactoid reaction
  • erythema multiforme
  • SLE exacerbation
  • porphyria exacerbation
  • chorea exacerbation
  • ocular lesions
  • breast CA risk (current, recent, or long-term use)
  • cervical CA risk

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@305685be
  • bleeding irregularities
  • nausea
  • vomiting
  • breast tenderness
  • headache
  • abdominal distension
  • abdominal pain
  • edema
  • weight changes
  • emotional lability
  • depression
  • acne
  • chloasma
  • libido changes
  • BP elevated
  • glucose intolerance
  • cholesterol incr.
  • contact lens intolerance
  • candidiasis, vulvovaginal

Safety/Monitoring .

Monitoring Parameters
glucose if pre-diabetes/diabetes; lipid panel if hyperlipidemia; BP if HTN, HTN-related disease, or renal disease

Look/Sound-Alike Drug Names
norgestrel/ethinyl estradiol confused with: desogestrel/ethinyl estradiol; levonorgestrel/ethinyl estradiol; norgestimate/ethinyl estradiol

Pregnancy/Lactation .

Pregnancy

Clinical Summary

contraindicated during pregnancy as primary indication is contraception; no known risk of teratogenicity when inadvertently used during early pregnancy based on human data

Lactation

Clinical Summary

Emergency Contraceptive Use: avoid breastfeeding x3-4h after tx; no known risk of infant harm based on limited human data; no known adverse effects on milk production based on limited human data

All Other Uses: avoid use while breastfeeding if <6wk postpartum, use non-hormonal or progestogen-only alternative; weigh risk/benefit while breastfeeding if >6wk postpartum; no human data available to assess risk of infant harm; possible risk of infant gynecomastia based on limited human data with higher estrogen doses and drug properties; decr. milk production, especially during early postpartum, based on limited human data with estrogens, conflicting human data with progestogens, and drug's mechanism of action

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@46845bdd

Metabolism: for norgestrel: liver; CYP450: 3A4 substrate; for ethinyl estradiol: GI tract, liver; CYP450: 3A4 substrate

Excretion: for norgestrel: urine, feces; Half-life: 8-13h; for ethinyl estradiol: urine 22-58%, feces 30-53%, bile 26-43%; Half-life: 26h

Subclass: Contraceptives, Emergency ; Contraceptives, Oral 1: Monophasic Estrogen/Progestogen OCPs

Mechanism of Action
for norgestrel/ethinyl estradiol: suppresses LH and FSH, inhibiting ovulation; alters cervical mucus and endometrium

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Lupin Pharmaceuticals, Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@17bf81e2

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information